<?xml version="1.0" encoding="UTF-8"?>
<p>Haematology patients were shown to be particularly vulnerable to SARS‐CoV‐2 infection
 <xref rid="bjh17168-bib-0003" ref-type="ref">
  <sup>3</sup>
 </xref> and in need of shielding; hence alternative management plans and new ways of delivering care were implemented wherever possible to reduce individual patient susceptibility.
 <xref rid="bjh17168-bib-0004" ref-type="ref">
  <sup>4</sup>
 </xref> Various clinical guidelines were issued at unprecedented speed, including recommendations for multiple myeloma (MM) and patients needing stem cell transplantation (SCT).
 <xref rid="bjh17168-bib-0005" ref-type="ref">
  <sup>5</sup>
 </xref>, 
 <xref rid="bjh17168-bib-0006" ref-type="ref">
  <sup>6</sup>
 </xref>, 
 <xref rid="bjh17168-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="bjh17168-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref> Conducting clinical trials in this environment poses unique challenges, having to strike a balance between patient safety, maintaining trial integrity, and ensuring adherence to good clinical practice (GCP) standards. The EMA, the EU Commission and the UK MHRA all published guidance to help stakeholders better manage clinical trials during the COVID‐19 pandemic.
 <xref rid="bjh17168-bib-0009" ref-type="ref">
  <sup>9</sup>
 </xref>, 
 <xref rid="bjh17168-bib-0010" ref-type="ref">
  <sup>10</sup>
 </xref>, 
 <xref rid="bjh17168-bib-0011" ref-type="ref">
  <sup>11</sup>
 </xref>
</p>
